Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03PWD
|
|||
| Former ID |
DIB014124
|
|||
| Drug Name |
GMI-1271
|
|||
| Synonyms |
Uproleselan
Click to Show/Hide
|
|||
| Drug Type |
?
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 3 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [2] | ||
| Company |
Glycomimetics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C60H109N3O27
|
|||
| Canonical SMILES |
CCC1CC(CC(C1OC2C(C(C(C(O2)C)O)O)O)OC3C(C(C(C(O3)CO)O)OC(CC4CCCCC4)C(=O)O)NC(=O)C)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC
|
|||
| InChI |
1S/C60H109N3O27/c1-5-44-38-45(39-46(55(44)90-60-54(70)53(69)51(67)41(2)86-60)88-59-50(63-42(3)65)56(52(68)48(40-64)89-59)87-47(58(72)73)37-43-9-7-6-8-10-43)57(71)62-13-12-61-49(66)11-14-75-17-18-77-21-22-79-25-26-81-29-30-83-33-34-85-36-35-84-32-31-82-28-27-80-24-23-78-20-19-76-16-15-74-4/h41,43-48,50-56,59-60,64,67-70H,5-40H2,1-4H3,(H,61,66)(H,62,71)(H,63,65)(H,72,73)/t41-,44-,45+,46+,47-,48+,50+,51+,52-,53+,54-,55+,56+,59+,60-/m0/s1
|
|||
| InChIKey |
LYSYOXNOOPBOSC-NGSKMYNLSA-N
|
|||
| CAS Number |
CAS 1983970-12-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | E-selectin (SELE) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| TNF signaling pathway | ||||
| African trypanosomiasis | ||||
| Malaria | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| ID Signaling Pathway | ||||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | |||
| Glucocorticoid receptor regulatory network | ||||
| ATF-2 transcription factor network | ||||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| TNF alpha Signaling Pathway | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of glycomimetics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.